This is a randomized, double-blind, placebo-controlled study that assessed the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate Alzheimer's disease (AD) dementia.

开始日期2019-03-28

申办/合作机构

Quince Therapeutics, Inc.

NCT03418688

/ Completed临床1期

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease

The study is a randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety and tolerability of ascending repeat doses of COR388 HCl in older healthy male and female subjects and a cohort of Alzheimer's disease subjects.

开始日期2018-03-06

申办/合作机构

Quince Therapeutics, Inc.

NCT03331900

/ Completed临床1期

A Phase 1 Single Ascending Dose Study of COR388 HCl

The study is a randomized, double-blind, placebo-controlled, dose escalation, first-in-human trial of the safety and tolerability of COR388 HCl in healthy male and female subjects.

开始日期2017-12-11

申办/合作机构

Quince Therapeutics, Inc.

100 项与 Atuzaginstat 相关的临床结果

登录后查看更多信息

100 项与 Atuzaginstat 相关的转化医学

登录后查看更多信息

100 项与 Atuzaginstat 相关的专利（医药）

登录后查看更多信息

项与 Atuzaginstat 相关的文献（医药）

2022-10-03·Expert opinion on investigational drugs

COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease

Article

作者: Sabbagh, Marwan N. ; Decourt, Boris

INTRODUCTION:

Evidence from in vitro and in vivo studies demonstrates that amyloid beta (Aβ) oligomers have potent, broad-spectrum antimicrobial properties created by fibrils that entrap pathogens and disrupt their membranes. Data suggest that Aβ may play a protective role in the innate immune response to microbial infections and that Aβ in the brain plays a damaging role when the inflammatory response is not well controlled.

AREAS COVERED:

This paper describes the relationship between periodontal disease and Alzheimer disease (AD), the role of Porphyromonas gingivalis and its secreted gingipains in AD, and the potential of the gingipain inhibitor atuzaginstat (COR388) to modulate AD neuropathologies.

EXPERT OPINION:

P. gingivalis is opsonized by Aβ42, is capable of entering the brain, and is an accelerant of neuropathologies in rodent models of AD. Thus, in our opinion, this bacteria is highly likely to be a pathogen capable of initiating or precipitating the progression of AD, which agrees with the pathogen hypothesis of clinical AD development.

2021-01-01·Neural regeneration research2区 · 医学

Oral frailty and neurodegeneration in Alzheimer’s disease

2区 · 医学

ReviewOA

作者: Dibello, Vittorio ; Panza, Francesco ; Sardone, Rodolfo ; Manfredini, Daniele ; Lobbezoo, Frank ; Lozupone, Madia ; Zupo, Roberta ; Dibello, Antonio ; Daniele, Antonio

Frailty is a critical intermediate status of the aging process with a multidimensional and multisystem nature and at higher risk for adverse health-related outcomes, including falls, disability, hospitalizations, institutionalization, mortality, dementia, and Alzheimer's disease. Among different frailty phenotypes, oral frailty has been recently suggested as a novel construct defined as a decrease in oral function with a coexisting decline in cognitive and physical functions. We briefly reviewed existing evidence on operational definitions of oral frailty, assessment and screening tools, and possible relationships among oral frailty, oral microbiota, and Alzheimer's disease neurodegeneration. Several underlying mechanism may explain the oral health-frailty links including undernutrition, sarcopenia linked to both poor nutrition and frailty, psychosocial factors, and the chronic inflammation typical of oral disease. Oral microbiota may influence Alzheimer's disease risk through circulatory or neural access to the brain and the interplay with periodontal disease, often causing tooth loss also linked to an increased Alzheimer's disease risk. On this bases, COR388, a bacterial protease inhibitor targeting Porphyromonas gingivalis implicated in periodontal disease, is now being tested in a double-blind, placebo-controlled Phase II/III study in mild-to-moderate Alzheimer's disease. Therefore, oral status may be an important contributor to general health, including Alzheimer's disease and late-life cognitive disorders, suggesting the central role of preventive strategies targeting the novel oral frailty phenotype and including maintenance and improvement of oral function and nutritional status to reduce the burden of both oral dysfunction and frailty.

2020-12-28·Journal of Alzheimer's disease reports

Porphyromonas gingivalis is a Strong Risk Factor for Alzheimer’s Disease

Review

作者: Welbury, Richard ; Singhrao, Sim K. ; Chukkapalli, Sasanka S. ; Kanagasingam, Shalini

Porphyromonas gingivalis ( P. gingivalis) is one of the several important bacterial pathogens associated with the sporadic Alzheimer’s disease (AD). Different serotypes are either capsulated or are non-capsulated. It has been demonstrated that P. gingivalis (non-capsulated) can reproduce the neurodegenerative AD-like changes in vitro, and a capsular P. gingivalis (strain W83) could reproduce the cardinal hallmark lesions of AD in a wild-type mouse model. All P. gingivalis forms express proteolytically active proteases that enable cleavage of the amyloid-β protin precursor (AβPP) and tau resulting in the formation of amyloid-β and neurofibrillary tangles. Tau is an established substrate for gingipains, which can cleave tau into various peptides. Some of the P. gingivalis fragmented tau protein peptides contain “VQIINK” and “VQIVYK” hexapeptide motifs which map to the flanking regions of the microtubule binding domains and are also found in paired helical filaments that form NFTs. P. gingivalis can induce peripheral inflammation in periodontitis and can also initiate signaling pathways that activate kinases, which in turn, phosphorylate neuronal tau. Periodontal disease related inflammation has metabolic implications for an individual’s peripheral and brain health as patients suffering from generalized periodontitis often have related co-morbidities and are “at risk” of developing AD. The aim here is to discuss the role of P. gingivalis behind such associations with the backdrop of huge efforts to test P. gingivalis virulence factors clinically (GAIN Trial: Phase 2/3 Study of COR388 in Subjects with AD) with inhibitors, which may lead to an intervention by reducing the pathogenic bacterial load.

项与 Atuzaginstat 相关的新闻（医药）

2025-01-02

·贝壳社

CNS新药即将迎来大爆发时代

▲点击图片，了解详情作者：黄仲平随着社会的前进和生活质量的提升，人类的预期寿命在不断增长，老龄化的步伐也在加快，随之而来的是中枢神经系统（CNS）疾病的发病率也在逐步上升，如帕金森病和阿尔兹海默症等老年性疾病对人类的健康和生活质量构成了严重威胁。同时，生活节奏的加快和竞争的加剧带来了更大的精神压力，这导致了失眠和抑郁症等精神障碍的发病率急剧增加。不断上升的患病数量为全球中枢神经类药物市场不断扩容，正在催化越来越多的CNS新药诞生。遗忘得到减缓对中国的阿尔茨海默症患者来说，2024年是个幸运年：年初，卫材的仑卡奈单抗（Lecanemab）登场；年末，礼来的多奈单抗（Donanemab）获批。不过这也意味着，仑卡奈单抗和多奈单抗将在中国市场产生正面碰撞，谁能更胜一筹？仑卡奈单抗针对早期阿尔兹海默症的Ⅲ期试验结果显示：接受治疗18个月后，仑卡奈单抗组和安慰剂组的临床痴呆评分总和（CDR-SB）评分分别为1.21和1.66。相较安慰剂组，仑卡奈单抗组CDR-SB评分低0.45，评分增速降低了27%。基于观察到的数据和外推至30个月的CDR-SB进行的斜率分析，接受仑卡奈单抗治疗25.5个月相当于安慰剂治疗18个月时的水平，这表明仑卡奈单抗可以延缓疾病进展达7.5个月。多奈单抗的III期临床研究TRAILBLAZER-ALZ 2结果显示：与安慰剂组相比，接受多奈单抗治疗组患者的综合阿尔茨海默病评定量表（iADRS）评分下降速度减缓了35%，临床痴呆评定量表总和评分（CDR-SB）较安慰剂组下降速度减缓了36%，并且阿尔茨海默病合作研究日常生活活动量表（ADCS iADL）评分显示疾病进展速度延缓了40%。单纯从数据上看，两者并没有特别显著的差异。全球市场中，还有一款阿杜卡尼单抗（Aducanumab）于2021年6月获美国FDA批准上市。但阿杜卡尼单抗商业化表现远低于市场预期，2021年和2022年销售额仅有300万美元和480万美元。雪上加霜的是，多奈单抗在头对头试验中击败了阿杜卡尼单抗，几乎截断了其商业化前景。阿杜卡尼单抗、仑卡奈单抗和多奈单抗临床数据对比，来源：太平洋证券研报这三款近年诞生的阿尔茨海默症新药均为Aβ单克隆抗体，使得以β-淀粉样蛋白斑块为靶点的治疗策略成为主流。但这并不意味着这一路线就是绝对正确。阿尔茨海默症的发病机制复杂，至今仍未完全破译具体机制。目前致病机制主要存在三大主流假说：Aβ类淀粉样蛋白级联假说、Tau蛋白异常磷酸化假说和胆碱能假说。三大假说均出现了多条针对性的技术路线。据统计，全球阿尔兹海默病在研新药超600款，多路线正在齐头并进。 Remternetug是礼来的一款给药方式灵活的靶向N3pG淀粉样蛋白亚型的抗体药物；ALZ-801是Alzheon研发的一款针对淀粉样蛋白聚集和神经毒性的口服小分子抑制剂；Galectin-3是TrueBinding研发的一种可溶性的β-半乳糖苷结合蛋白；Semorinemab是一种人源化的抗tau IgG4单克隆抗体，由基因泰克开发；Atuzaginstat是一款牙龈菌蛋白酶（gingipain）抑制剂，可以降低牙龈卟啉单胞菌毒性，降低细菌负荷，从而改善阿尔茨海默症进展；ATH-1017是一种小分子药物，旨在增强肝细胞生长因子在其受体MET上的活性，由Athira Pharma开发等等等等。国内方面，2019年11月上海绿谷研发的甘露特纳获批上市，通化金马的1.1类新药AChE抑制剂琥珀八氢氨吖啶已提交NDA。除此之外，国内自研生物创新药和化学创新药多数尚处于早期临床阶段，研发靶点也呈现多样化态势，并且出现了中药产品。恒瑞医药的国产Aβ单抗SHR-1707处于Ib期临床；先声药业从Vivoryon Therapeutics引进的一种靶向神经毒性淀粉样蛋白N3pE(pGlu-Aβ)的口服小分子谷氨酰肽环转移酶（QPCT）抑制剂处于临床Ⅱb期；康弘药业的6.1类中药创新药KH110（五加益智颗粒）处于临床Ⅱ期；悦康药业的中药1.1类新药复方银杏叶片进入NDA阶段...... 尽管在研发方面，各种路线都在十分努力地证明自己，但从临床试验数据中我们也看到，这些都不是治疗阿尔兹海默症真正有效的药物。道路总是曲折的，随着越来越多的新药上市，曙光似乎就在眼前。颤抖得到减轻帕金森病是继阿尔茨海默症后第二常见的神经系统退行性疾病，主要以黑质多巴胺能神经元进行性退变和路易小体形成的病理变化，以及纹状体区多巴胺递质降低、多巴胺与乙酰胆碱递质失平衡的生化改变为显著特征。临床主要表现为震颤、肌强直、动作迟缓、姿势平衡障碍的运动症状和睡眠障碍、嗅觉障碍、自主神经功能障碍、认知和精神障碍等非运动症状。流行病学调查研究显示欧美国家60岁以上帕金森病患病率达到1%，80岁以上超过4%，我国65岁以上人群患病率为1.7%。迄今为止，帕金森病的治疗仅能改善症状，无法阻止病情发展。由于目前帕金森病发病机制并不明确，因此对帕金森病研发也存在多种技术路线之争，主要包括对症治疗（ST）路线和疾病修饰疗法（DMT）路线。全球范围内，帕金森病在研管线阶段及靶点分类，来源：太平洋证券研报从靶点分类看，对症治疗（ST）仍以多巴胺能靶点为主，目前有多个在研处于III期阶段，其中艾伯维开发的ABBV-951（foslevodopa/foscarbidopa）和Cerevel开发的Tavapadon关注度较高。 ABBV-951是一款左旋多巴和卡比多巴前体药物，可显著改善晚期帕金森病患者的运动并发症，已于2024年10月获美国FDA批准上市，是首款基于左旋多巴的24小时皮下连续输注疗法；Tavapadon为一款高选择性D1/D5受体部分激动剂，有潜力成为早期帕金森病单药治疗和晚期帕金森病辅助治疗药物。随着对帕金森病发病机制的深入研究，疾病修饰疗法（DMT）逐渐成为近年来新药研发的热点。其中也存在多种不同方向技术路线，包括的对热门靶点α-突触核蛋白（α-syn）的研究，以及细胞疗法、肠道菌群疗法、GLP-1受体激动剂等。 Buntanetap是Annovis Bio开发的一种可阻断mRNA翻译表达神经毒性蛋白的小分子抑制剂；IKT-148009是一种小分子c-Abl激酶抑制剂，可降低c-Abl激酶的活性；Lu AF82422是一种靶向α-syn C末端的人免疫球蛋白G1（IgG1）单克隆抗体；BIIB122是Denali开发的一款小分子LRRK2激酶抑制剂...... 国内方面，目前已有多款创新制剂上市，以及超21款帕金森病在研新药物。其中以跃赛生物的干细胞技术和恒瑞医药的双基因药物最为受关注。跃赛生物自主研发针对帕金森病的iPSC来源细胞药物产品UX-DA001注射液（人中脑多巴胺能神经前体细胞注射液）获得CDE的临床试验默示许可，成功进入临床试验阶段，这一突破标志着国内在神经退行性疾病治疗领域的一项重要进展。 RGL-193是恒瑞医药自主研发的一款候选双基因AAV治疗药物，采用立体定向技术注入患者脑内，提高左旋多巴的转化效率，目前已完成首例患者给药。从市场规模看，目前国内帕金森病仅30余亿元，对标发达国家，渗透率有非常大的增长空间。随着人口老龄化程度持续加深，帕金森病患者人数将快速增加，具有明确疗效的新药不断获批，市场规模或将迎来大规模跃升。新机制药物接二连三诞生在治疗手段上，与肿瘤、自身免疫性疾病等相比，CNS领域药物研发进度缓慢。但如上文所述，阿尔茨海默病、帕金森病等领域近年来逐渐出现新机制药物获批，研发困境逐步反转，精神分裂症、抑郁症、偏头痛、失眠等领域都迎来或正在迎来诸多突破性进展。精神分裂症方面，新机制药物KarXT于2024年9月成功获得美国FDA批准，标志着精神分裂症治疗正式进入“后多巴胺”时代。KarXT是继20世纪50年代初第一代抗精神病药氯丙嗪诞生后，70年来首款采用全新作用机制的抗精神病药物。 KarXT最初由Karuna研发，制药巨头BMS看到了这款药物的潜力，于2023年底以140亿美元价格收购Karuna，再鼎医药拥有KarXT的大中华区权益，并正在参与其多个全球临床研究。抑郁症方面，近年来同样有所突破，临床上有探索新机制和在传统分子上进行再开发的策略。这其中，来自国内制药企业绿叶制药的托鲁地文拉法辛的获批，创造了国产创新药在抑郁症治疗领域取得的里程碑式的“零”的突破。新机制的探索路径上，针对单胺通路，COMPASS Pathways开发了针对受体的激动剂COMP360；NMDA拮抗剂带代表药物有安非他酮和右美沙芬的复方制剂Auvelity等。失眠治疗药物方面，新靶点药物上市速度正在加快，成功开发的有食欲素受体拮抗剂和GABAA正向调节剂。食欲素受体拮抗剂代表药物有默沙东的苏沃雷生，Idorsia的Daridorexant；GABAA正向调节剂代表药物有京新药业的地达西尼，于2023年国内获批上市，服用后平均睡眠时间均可延长，不改变睡眠结构，且未发现依赖性、反跳性失眠、戒断症状和药物滥用证据。结语由于中枢神经系统不具有再生能力，加之对神经元运作的机制了解并不全面，这也造成了中枢系统疾病新药研发的难度。但自2022年起，CNS领域新机制研发药物日臻成熟，引起了MNC的强烈关注，开始逐步加码CNS领域的收购和BD，除上文提到的BMS收购Karuna外，辉瑞、艾伯维、默沙东等均现大额并购案，眼见着CNS领域的一场争夺战即将打响。国内布局了CNS研发的药企，如翰森制药、绿叶制药或许有望乘风而上。后续发展如何，贝壳社还将持续关注。参考资料： 1、各大上市公司官网、公告、年报等 2、太平洋证券、招商证券、智银资本等研报 3、《CNS的冰与火之歌》，氨基观察，2024-12-25 4、《每4周注射一次！礼来阿尔茨海默病新药在国内获批》，人民日报，2024-12-18 5、《全国首款！全球第二款!保税区域生物医药产业又传喜报》，上观，2024-12-25 关于贝壳社贝壳社是国内领先的医健创新创业服务平台，为医健创业者提供全路径创业服务。通过产业空间运营、创业教育、投资孵化、数字化赋能、企业价值增长等服务体系，给医健创业企业提供产业空间、人才战略培养、投融资、产业生态资源、数字化转型等服务。同时，贝壳社布局澳洲，帮助国内生物医药企业加速走向海外；成立“泰格-泰珑-贝壳社企业经营服务中心”为企业成长提供全生命周期的增值服务，提高企业运营效率，加快企业成长发展。我们深度链接政府、科研院所、临床机构、投资机构、第三方服务商、CXO等行业资源，致力于赋能医疗健康创业公司成长，推动创新技术造福人类生命健康。往期推荐 1 越来越多Biotech发起“独立宣言” 2 多抗：下一个大药发展趋势 _ 3 围猎60亿美元大药 _ *声明：本文仅为作者观点，不构成任何投资建议，且非治疗方案推荐。投稿请添加小助手：bioclub666

上市批准临床3期抗体药物偶联物临床结果临床成功

2024-06-04

·Pharmaceutical Technology

FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex

The FDA has granted fast track designation to Quince Therapeutics’ Phase III drug candidate EryDex to treat rare disease ataxia-telangiectasia. Credit: grandbrothers via Shutterstock. California-based biotech Quince Therapeutics has won fast track designation from the US Food and Drug Administration (FDA) for its ataxia-telangiectasia (A-T) drug EryDex. Recommended Buyer's Guides Buyer's Guide Leading Guide to Packaging Materials, Containers and Containment Services for the Pharmaceutical Industry Buyer's Guide Leading Guide to Clinical Packaging Companies in contract Manufacturing for the Pharmaceutical Industry According to the 3 June announcement, fast track designation was awarded to address a high unmet medical need for patients with A-T. The status allows for earlier interactions with the FDA as Quince seeks accelerated approval, and also the possibility to undergo rolling reviews. A-T is a rare disease of the nervous and immune systems, affecting motor movement and speech. EryDex utilises autologous intracellular drug encapsulation (AIDE) technology to administer dexamethasone sodium phosphate (DSP) into a patient’s red blood cells. Red blood cells filled with DSP are then reinfused into the patient, allowing for the slow release of steroids over several weeks, without the long-term toxicity commonly associated with chronic administration. The FDA lifted a partial clinical hold that was on the drug in October 2023, advancing it into the Phase III NEAT study (NCT06193200). The FDA removed the partial clinical hold after requesting additional information on plastics used in the single-use EryKit, which is part of EryDex. Changes were made to comply with recent European regulations. The NEAT study will enrol approximately 86 six- to nine-year-old patients with A-T as the primary analysis population, as well as 20 patients over the age of ten years. Participants will be randomised between EryDex or placebo and treatment will involve six infusions once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last visit completion in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS). See Also: FDA hearing set to discuss advisory committee members’ conflicts and more Be Bio’s haemophilia B treatment gains FDA orphan drug status Quince shared in an April 2024 business update that it anticipates topline results in H2 2025 with a potential NDA submission in 2026. Quince inherited EryDex in July 2023 when it acquired biotech EryDel in a $485m deal in October 2023. Formerly known as Cortexyme, Quince changed its name in 2022 and focused on rare diseases following several setbacks, including a clinical hold on its Alzheimer’s disease drug atuzaginstat. In the announcement accompanying the fast track, Quince CEO Dirk Thye said: “The granting of fast track status for EryDex System marks another important milestone in our endeavour to identify a beneficial therapeutic solution for patients with A-T. “We have initiated our pivotal Phase III NEAT clinical trial, which is being conducted in the US, UK, and the European Union.”

快速通道临床3期并购孤儿药

2023-11-16

·PRNewswire

Lighthouse Pharmaceuticals Announces FDA Approval To Proceed With Phase 2 Spring Trial Of LHP588, A Next-Generation Treatment For P. Gingivalis-positive Alzheimer's Disease

Phase 1 single ascending and multiple ascending dose studies previously completed demonstrate safety, tolerability and dosing to reach optimal target engagement SAN FRANCISCO, Nov. 16, 2023 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of Alzheimer's and other diseases of aging, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for LHP588, the company's next-generation gingipain inhibitor, for the treatment of P. gingivalis-positive Alzheimer's disease. The "Study May Proceed" letter from the FDA was based on review of the comprehensive IND package including safety, chronic toxicology, manufacturing, Phase 1 human data, and the planned Phase 2 SPRING (Stopping PRogression of P. gINGivalis-positive Alzheimer's disease) trial protocol. LHP588 is a next-generation, brain penetrant small-molecule gingipain inhibitor that demonstrated safety and tolerability in the completed Phase 1 study, along with plasma levels sufficient to engage the target with just once-daily oral dosing. The Phase 2 SPRING clinical trial is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of once-a-day dosing of LHP588 for the treatment of P. gingivalis-positive mild to moderate Alzheimer's disease. 300 patients will be enrolled in the trial and randomized into three arms (placebo, 25 and 50 mg) for 48 weeks of treatment. Patients must have mild to moderate Alzheimer's disease and evidence of P. gingivalis infection, based on a saliva test. The GAIN trial of the first-generation gingipain inhibitor, atuzaginstat, demonstrated that patients with mild to moderate AD and a positive P. gingivalis saliva test had a dose-dependent, 57% slowing of cognitive decline on the prespecified proof of efficacy endpoint, ADAS-Cog11, compared to the placebo group (p = 0.02). "We are very pleased to have FDA clearance to initiate the SPRING Phase 2 clinical trial. Previous studies of this mechanism indicated promise of the precision medicine approach being leveraged by Lighthouse going forward. The clinical efficacy and safety data provided by the GAIN trial has enabled us to significantly de-risk the mechanism of action, maximize target engagement with higher exposures of LHP588, and implement the optimal clinical study design," said Casey Lynch, CEO of Lighthouse Pharmaceuticals. "LHP588 is a next-generation gingipain inhibitor that has been optimized for selectivity and metabolism, demonstrating an excellent safety profile in both human and toxicology studies. With FDA clearance in hand, we look forward to working with our clinical advisors and investors to move this important clinical study forward." About Lighthouse Pharmaceuticals Lighthouse Pharma is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs based on expertise in small molecule protease inhibition. Lighthouse's lead program, LHP588, a Phase 2 ready orally bioavailable small molecule, targets a specific, infectious pathogen, Porphyromonas gingivalis, which is associated with chronic degenerative and inflammatory disorders including dementia, periodontal disease, atherosclerosis, and orodigestive cancers. For more information, visit . SOURCE Lighthouse Pharmaceuticals

临床2期临床1期临床申请临床结果

100 项与 Atuzaginstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	美国	Quince Therapeutics, Inc.	2019-03-28
阿尔茨海默症	临床3期	法国	Quince Therapeutics, Inc.	2019-03-28
阿尔茨海默症	临床3期	荷兰	Quince Therapeutics, Inc.	2019-03-28
阿尔茨海默症	临床3期	波兰	Quince Therapeutics, Inc.	2019-03-28
阿尔茨海默症	临床3期	西班牙	Quince Therapeutics, Inc.	2019-03-28
阿尔茨海默症	临床3期	英国	Quince Therapeutics, Inc.	2019-03-28
牙周疾病	临床阶段不明	美国	Quince Therapeutics, Inc.	2020-03-06
帕金森病	临床前	美国	Quince Therapeutics, Inc.	2021-01-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03823404 (CTgov)	临床2/3期	阿尔茨海默症	643	COR388 (COR388 80 mg BID (Twice Daily))	製膚鬱襯夢鑰繭製廠襯(醖築願鑰鏇構淵選壓淵) = 鏇鏇淵壓鬱範範淵選淵顧積醖簾衊鬱範鑰窪鏇 (齋簾選鹹糧淵膚衊夢鹹, 8.8) 更多	-	2023-02-23
				COR388 (COR388 40 mg BID (Twice Daily))	製膚鬱襯夢鑰繭製廠襯(醖築願鑰鏇構淵選壓淵) = 鬱遞網壓鑰鏇顧鏇夢壓顧積醖簾衊鬱範鑰窪鏇 (齋簾選鹹糧淵膚衊夢鹹, 8.6) 更多